1-3 of 3
Connie Ceriotti
Close
Sort by
Journal Articles

A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Mark A Fiala, BS, CCRP, Jesse Keller, MD, Jeevan Sekhar, MD, Connie Ceriotti, RN, BSN, Camille N. Abboud, MD, John F DiPersio, MD PhD, Michael H. Tomasson, MD, Tanya M Wildes, MD MSCI, Keith Stockerl-Goldstein, Ravi Vij, MD MBA
Journal: Blood
Blood (2016) 128 (22): 3329.
https://doi.org/10.1182/blood.V128.22.3329.3329
Published: 2016
Journal Articles

Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Amanda F. Cashen, MD, Kendall Gosch, BA, Theresa Fletcher, MS, Connie Ceriotti, RN, BSN, Armin Ghobadi, MD, Ravi Vij, MD, Keith Stockerl-Goldstein, MD, John F Dipersio, MD PhD, Camille N Abboud, MD
Journal: Blood
Blood (2015) 126 (23): 3196.
https://doi.org/10.1182/blood.V126.23.3196.3196
Published: 2015
Journal Articles

A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma

Jesse Keller, MD, Mark A Fiala, BS, CCRP, Jeevan Sekhar, Connie Ceriotti, Melissa Allen, Camille N. Abboud, MD, Keith E. Stockerl-Goldstein, MD, Tanya M Wildes, MD MSCI, Michael H. Tomasson, MD, Ravi Vij, MBBS, MD
Journal: Blood
Blood (2014) 124 (21): 4731.
https://doi.org/10.1182/blood.V124.21.4731.4731
Published: 2014